Literature DB >> 22847762

Assessing the reproducibility of dynamic contrast enhanced magnetic resonance imaging in a murine model of breast cancer.

Stephanie L Barnes1, Jennifer G Whisenant, Mary E Loveless, Gregory D Ayers, Thomas E Yankeelov.   

Abstract

Quantitative dynamic contrast enhanced magnetic resonance imaging estimates parameters related to tissue vascularity and volume fractions; additionally, semiquantitative parameters such as the initial area under the curve can be utilized to describe tissue behavior. The aim of this study was to establish the reproducibility of quantitative and semiquantitative analysis of dynamic contrast enhanced magnetic resonance imaging in a murine model of breast cancer. For each animal, a T1-weighted, gradient-echo sequence was used to acquire two sets of dynamic contrast enhanced magnetic resonance imaging data separated by 5 h. Data were acquired at both a 0.05 mm3 (128(2) , n=12) and a 0.2 mm3 (64(2), n=12) resolution, and analysis was performed using both the Tofts-Kety (to estimate Ktrans and ve) and extended Tofts-Kety (Ktrans, ve, and vp) models. Reproducibility analysis was performed for both the center slice and the total tumor volume for all parameters. For the total volume analysis, the repeatability index for Ktrans is 0.073 min(-1) in the standard model analysis and 0.075 min(-1) in the extended model analysis at the 128(2) acquisition. For the 64(2) acquisition, the values are 0.089 and 0.063 min(-1) for the standard and extended models, respectively. The repeatability index for initial area under the curve was 0.0039 and 0.0042 mM min for the 128(2) and 64(2) acquisitions, respectively.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22847762      PMCID: PMC3740769          DOI: 10.1002/mrm.24422

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  33 in total

Review 1.  Measuring agreement in method comparison studies.

Authors:  J M Bland; D G Altman
Journal:  Stat Methods Med Res       Date:  1999-06       Impact factor: 3.021

2.  Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.

Authors:  Whitney B Pope; Hyun J Kim; Jing Huo; Jeffry Alger; Matthew S Brown; David Gjertson; Victor Sai; Jonathan R Young; Leena Tekchandani; Timothy Cloughesy; Paul S Mischel; Albert Lai; Phioanh Nghiemphu; Syed Rahmanuddin; Jonathan Goldin
Journal:  Radiology       Date:  2009-07       Impact factor: 11.105

3.  PET imaging of early response to the tyrosine kinase inhibitor ZD4190.

Authors:  Min Yang; Haokao Gao; Yongjun Yan; Xilin Sun; Kai Chen; Qimeng Quan; Lixin Lang; Dale Kiesewetter; Gang Niu; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03-01       Impact factor: 9.236

4.  Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.

Authors:  Ronan J Kelly; Arun Rajan; Jeremy Force; Ariel Lopez-Chavez; Corrine Keen; Liang Cao; Yunkai Yu; Peter Choyke; Baris Turkbey; Mark Raffeld; Liqiang Xi; Seth M Steinberg; John J Wright; Shivaani Kummar; Martin Gutierrez; Giuseppe Giaccone
Journal:  Clin Cancer Res       Date:  2011-01-11       Impact factor: 12.531

5.  Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis.

Authors:  Susan M Galbraith; Martin A Lodge; N Jane Taylor; Gordon J S Rustin; Søren Bentzen; J James Stirling; Anwar R Padhani
Journal:  NMR Biomed       Date:  2002-04       Impact factor: 4.044

6.  Simultaneous dynamic T1 and T2* measurement for AIF assessment combined with DCE MRI in a mouse tumor model.

Authors:  Melanie Heilmann; Christine Walczak; Julien Vautier; Jean-Luc Dimicoli; Carole D Thomas; Mihaela Lupu; Joël Mispelter; Andreas Volk
Journal:  MAGMA       Date:  2007-10-11       Impact factor: 2.310

7.  MRI estimation of the arterial input function in mice.

Authors:  Stephen Pickup; Rong Zhou; Jerry Glickson
Journal:  Acad Radiol       Date:  2003-09       Impact factor: 3.173

8.  Simultaneous measurement of arterial input function and tumor pharmacokinetics in mice by dynamic contrast enhanced imaging: effects of transcytolemmal water exchange.

Authors:  Rong Zhou; Stephen Pickup; Thomas E Yankeelov; Charles S Springer; Jerry D Glickson
Journal:  Magn Reson Med       Date:  2004-08       Impact factor: 4.668

9.  Modeling of contrast agent kinetics in the lung using T1-weighted dynamic contrast-enhanced MRI.

Authors:  Josephine H Naish; Lucy E Kershaw; David L Buckley; Alan Jackson; John C Waterton; Geoffrey J M Parker
Journal:  Magn Reson Med       Date:  2009-06       Impact factor: 4.668

Review 10.  Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

Authors:  P S Tofts; G Brix; D L Buckley; J L Evelhoch; E Henderson; M V Knopp; H B Larsson; T Y Lee; N A Mayr; G J Parker; R E Port; J Taylor; R M Weisskoff
Journal:  J Magn Reson Imaging       Date:  1999-09       Impact factor: 4.813

View more
  15 in total

1.  Assessing the accuracy and reproducibility of modality independent elastography in a murine model of breast cancer.

Authors:  Jared A Weis; Katelyn M Flint; Violeta Sanchez; Thomas E Yankeelov; Michael I Miga
Journal:  J Med Imaging (Bellingham)       Date:  2015-07-02

2.  Sequence design and evaluation of the reproducibility of water-selective diffusion-weighted imaging of the breast at 3 T.

Authors:  He Zhu; Lori R Arlinghaus; Jennifer G Whisenant; Ming Li; John C Gore; Thomas E Yankeelov
Journal:  NMR Biomed       Date:  2014-07-01       Impact factor: 4.044

3.  An analysis of the uncertainty and bias in DCE-MRI measurements using the spoiled gradient-recalled echo pulse sequence.

Authors:  Ergys Subashi; Kingshuk R Choudhury; G Allan Johnson
Journal:  Med Phys       Date:  2014-03       Impact factor: 4.071

4.  Selection of Fitting Model and Arterial Input Function for Repeatability in Dynamic Contrast-Enhanced Prostate MRI.

Authors:  Sharon Peled; Mark Vangel; Ron Kikinis; Clare M Tempany; Fiona M Fennessy; Andrey Fedorov
Journal:  Acad Radiol       Date:  2018-11-20       Impact factor: 3.173

5.  Techniques and applications of dynamic contrast enhanced magnetic resonance imaging in cancer.

Authors:  Stephanie L Barnes; Jennifer G Whisenant; Thomas E Yankeelov
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2014

6.  A comparison of individual and population-derived vascular input functions for quantitative DCE-MRI in rats.

Authors:  David A Hormuth; Jack T Skinner; Mark D Does; Thomas E Yankeelov
Journal:  Magn Reson Imaging       Date:  2014-01-07       Impact factor: 2.546

Review 7.  Methods and challenges in quantitative imaging biomarker development.

Authors:  Richard G Abramson; Kirsteen R Burton; John-Paul J Yu; Ernest M Scalzetti; Thomas E Yankeelov; Andrew B Rosenkrantz; Mishal Mendiratta-Lala; Brian J Bartholmai; Dhakshinamoorthy Ganeshan; Leon Lenchik; Rathan M Subramaniam
Journal:  Acad Radiol       Date:  2015-01       Impact factor: 3.173

Review 8.  MR Imaging Biomarkers in Oncology Clinical Trials.

Authors:  Richard G Abramson; Lori R Arlinghaus; Adrienne N Dula; C Chad Quarles; Ashley M Stokes; Jared A Weis; Jennifer G Whisenant; Eduard Y Chekmenev; Igor Zhukov; Jason M Williams; Thomas E Yankeelov
Journal:  Magn Reson Imaging Clin N Am       Date:  2016-02       Impact factor: 2.266

9.  Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results.

Authors:  Anna G Sorace; C Chad Quarles; Jennifer G Whisenant; Ariella B Hanker; J Oliver McIntyre; Violeta M Sanchez; Thomas E Yankeelov
Journal:  Breast Cancer Res Treat       Date:  2016-01-20       Impact factor: 4.872

10.  Practical dynamic contrast enhanced MRI in small animal models of cancer: data acquisition, data analysis, and interpretation.

Authors:  Stephanie L Barnes; Jennifer G Whisenant; Mary E Loveless; Thomas E Yankeelov
Journal:  Pharmaceutics       Date:  2012       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.